S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:CMRX - Chimerix Stock Price, Forecast & News

$1.67
+0.03 (+1.83 %)
(As of 02/17/2020 04:00 PM ET)
Today's Range
$1.62
Now: $1.67
$1.68
50-Day Range
$1.64
MA: $1.91
$2.33
52-Week Range
$1.25
Now: $1.67
$4.40
Volume208,903 shs
Average Volume299,119 shs
Market Capitalization$102.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.22 million
Book Value$3.50 per share

Profitability

Net Income$-69,470,000.00
Net Margins-1,162.96%

Miscellaneous

Employees82
Market Cap$102.50 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.


Chimerix (NASDAQ:CMRX) Frequently Asked Questions

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) announced its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The biopharmaceutical company had revenue of $1.96 million for the quarter, compared to analysts' expectations of $1.30 million. Chimerix had a negative net margin of 1,162.96% and a negative return on equity of 38.75%. View Chimerix's Earnings History.

When is Chimerix's next earnings date?

Chimerix is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Chimerix.

What price target have analysts set for CMRX?

3 Wall Street analysts have issued 12-month price targets for Chimerix's shares. Their forecasts range from $2.00 to $7.00. On average, they expect Chimerix's share price to reach $4.00 in the next year. This suggests a possible upside of 139.5% from the stock's current price. View Analyst Price Targets for Chimerix.

What is the consensus analysts' recommendation for Chimerix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.

Has Chimerix been receiving favorable news coverage?

Press coverage about CMRX stock has been trending very negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Chimerix earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Chimerix.

Are investors shorting Chimerix?

Chimerix saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 853,700 shares, a decline of 27.0% from the January 15th total of 1,170,000 shares. Based on an average trading volume of 721,100 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.9% of the shares of the company are short sold. View Chimerix's Current Options Chain.

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

Who are Chimerix's key executives?

Chimerix's management team includes the folowing people:
  • Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
  • Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
  • Mr. Michael A. Sherman, CEO & Pres (Age 53)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier Ph.D., Chief Science Officer

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.81%), State Street Corp (1.99%), AQR Capital Management LLC (1.70%), Acadian Asset Management LLC (1.38%), UBS Group AG (0.95%) and Jacobs Levy Equity Management Inc. (0.94%). Company insiders that own Chimerix stock include Ernest Mario, Fred A Middleton, Garrett Nichols, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Institutional Ownership Trends for Chimerix.

Which institutional investors are selling Chimerix stock?

CMRX stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Alambic Investment Management L.P., Goldman Sachs Group Inc., Bank of America Corp DE and Rhumbline Advisers. View Insider Buying and Selling for Chimerix.

Which institutional investors are buying Chimerix stock?

CMRX stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, Panagora Asset Management Inc., Acadian Asset Management LLC, Ikarian Capital LLC, State Street Corp, Jacobs Levy Equity Management Inc. and AJO LP. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Insider Buying and Selling for Chimerix.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $1.67.

How big of a company is Chimerix?

Chimerix has a market capitalization of $102.50 million and generates $7.22 million in revenue each year. The biopharmaceutical company earns $-69,470,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 82 workers across the globe.View Additional Information About Chimerix.

What is Chimerix's official website?

The official website for Chimerix is http://www.chimerix.com/.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]


MarketBeat Community Rating for Chimerix (NASDAQ CMRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  339 (Vote Outperform)
Underperform Votes:  359 (Vote Underperform)
Total Votes:  698
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel